Across TCGA pan-cancer cohorts, SLC6A9 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SLC6A9’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SLC6A9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC6A9 is over-expressed in tumor, although a few such as COAD and KIRP show the opposite, repressed pattern.
LIHC, COAD, and BRCA are the cancer types where SLC6A9 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC6A9 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.